[Featured Stock] Jinwon Life Sciences Gains Attention as Omicron-Related Stock

On the 23rd, Jungbu Market in Jung-gu, Seoul, was quiet. There have been a total of 199 confirmed COVID-19 cases related to Jungbu Market. The Seoul Metropolitan Government tested a total of 687 people, including contacts. Excluding the initial confirmed case, 198 tested positive, 451 tested negative, and the rest are awaiting results. Workers at the facility shared restrooms and other common areas, and it was difficult for employees of nearby stores to maintain social distancing. It was confirmed that some confirmed cases continued to work even after showing COVID-19 symptoms. Photo by Moon Ho-nam munonam@

[Asia Economy Reporter Hwang Junho] On the 3rd, the stock price of Genexine, a biopharmaceutical manufacturer, is soaring.

As of 10:52 AM on the same day, Genexine's stock price is trading at 23,050 KRW, up 16.12% compared to the previous day.

Genexine is a COVID-19 vaccine-related stock. According to the industry, Innovio, which shares research and development projects with Genexine's subsidiary CGXI, has reportedly started preclinical development of a specific DNA vaccine candidate related to Omicron.